Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07256652 · ClinicalTrials.gov registry record · NA
How Does YES Bar Affect Blood Glucose Levels?
A NA study of Blood Glucose Monitoring, sponsored by Efforia.
- Recruiting
- Registry status
- NA
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT07256652: Recruiting NA study of Blood Glucose Monitoring, sponsored by Efforia.
NCT07256652 is a NA study of Blood Glucose Monitoring that is actively recruiting participants, run by Efforia. The registered enrollment target is 100 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07256652, a NA study of Blood Glucose Monitoring, is actively recruiting participants, sponsored by Efforia.
- RECRUITING
- Registry status
- NA
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
Curious to see if there is a sweet treat that doesn't spike your blood sugar (avoiding the energy crash, inflammation, and weight gain)? This study uses the Abbott Lingo CGM to see how your blood glucose levels responds to YES Bar-an all natural, gluten-free, plant-based bar that tastes like dessert. You'll track your levels before and after eating it to see if it fits into your metabolic health. (iOS Only)
Primary Outcome
Timed Blood Glucose Monitoring for a Specific Food is an invaluable tool for understanding individual metabolic responses to food intake. This survey involves using a continuous glucose monitor (CGM) to record blood glucose levels after consuming a specific food, helping to pinpoint how different foods impact blood sugar levels over a certain period. The data collected can significantly aid in optimizing dietary choices by demonstrating the foods that cause glucose spikes or maintain stability.
Conditions Studied
Interventions
- OTHER YES Bar
Study Locations (1)
New York
- Efforia - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2025-08-25 |
| Est. Completion | 2026-08-25 |
| Phase | NA |
What NCT07256652 shows while recruiting
NCT07256652 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Blood Glucose Monitoring appearing as the primary indexed condition, and to 1 intervention - of which YES Bar is the first listed.
NCT07256652 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT07256652 about?
NCT07256652 is a clinical study titled "How Does YES Bar Affect Blood Glucose Levels?". Curious to see if there is a sweet treat that doesn't spike your blood sugar (avoiding the energy crash, inflammation, and weight gain)? This study uses the Abbott Lingo CGM to see how your blood glucose levels responds to YES Bar-an all natural, gluten-free, plant-based bar that tastes like dessert...
What is the current status of trial NCT07256652?
This trial is currently recruiting. It is a NA study. The enrollment target is 100 participants. The study started on 2025-08-25. Estimated completion is 2026-08-25.
What conditions does trial NCT07256652 study?
This clinical trial studies the following conditions: Blood Glucose Monitoring.
What interventions are being tested in trial NCT07256652?
The interventions under investigation include: YES Bar (OTHER).
Who is sponsoring clinical trial NCT07256652?
This trial is sponsored by Efforia, which has 19 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07256652 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07256652's enrollment target sits among peer trials
100 840th of 2000 higher than 1,081 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI